A human monoclonal antibody blocking SARS-CoV-2 infection
Abstract The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV). This cross-neutralizing antibody targets a communal epitope on these viruses and offers potential for prevention and treatment of COVID-19..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
bioRxiv.org - (2020) vom: 10. Juli Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Chunyan [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.03.11.987958 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI000803693 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI000803693 | ||
| 003 | DE-627 | ||
| 005 | 20230429092413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200327s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.03.11.987958 |2 doi | |
| 035 | |a (DE-627)XBI000803693 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.03.11.987958 | ||
| 035 | |a (biorXiv)10.1101/2020.03.11.987958 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Wang, Chunyan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A human monoclonal antibody blocking SARS-CoV-2 infection |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV). This cross-neutralizing antibody targets a communal epitope on these viruses and offers potential for prevention and treatment of COVID-19. | ||
| 700 | 1 | |a Li, Wentao |e verfasserin |4 aut | |
| 700 | 1 | |a Drabek, Dubravka |e verfasserin |4 aut | |
| 700 | 1 | |a Okba, Nisreen M.A. |e verfasserin |4 aut | |
| 700 | 1 | |a van Haperen, Rien |e verfasserin |4 aut | |
| 700 | 1 | |a Osterhaus, Albert D.M.E. |e verfasserin |4 aut | |
| 700 | 1 | |a van Kuppeveld, Frank J.M. |e verfasserin |4 aut | |
| 700 | 1 | |a Haagmans, Bart L. |e verfasserin |4 aut | |
| 700 | 1 | |a Grosveld, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Berend-Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 10. Juli |
| 773 | 1 | 8 | |g year:2020 |g day:10 |g month:07 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-020-16256-y |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.03.11.987958 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 10 |c 07 | ||
| 953 | |2 045F |a 570 | ||